Department of Immunology and Histocompatibility, Saint Louis Hospital, Paris, France.
Research Department of St Louis, INSERM UMR976, University Paris Cite, Paris, France.
HLA. 2024 Oct;104(4):e15700. doi: 10.1111/tan.15700.
Eplet 52SK is unique in the HLA eplet registry as targeting the whole family of DQA101 alleles. It is proposed as an antibody-verified eplet but has not been validated enough to deserve this label. Especially, confusion can occur with reactivity targeting the 52PQ eplet which is present on the DQB105 and DQB106 alleles families, as DQ molecule stability imposes DQA101 to selectively associate with these DQ-β families only. Using two Luminex single antigen (LSA) assays from two vendors, beads bearing DR-α/DQ6 heterodimers, a special build LSA panel of additional DQ beads, and an adsorption/elution strategy relying on cells from deceased donors or recombinant cells solely expressing one DQ antigen, we definitely established the antibody-verified status of eplet 52SK using patients' sera reacting only against the DQ5 and DQ6 beads of the One Lambda LSA panel in routine patients' follow up. We also show that reactivity against this eplet is not a rare event among anti-DQ1 immunisation. This study further strengthens the importance of considering the DQA1 locus in immunological studies of HLA and in organ allocation strategies.
Eplet 52SK 在 HLA eplet 注册中心是独一无二的，因为它针对的是整个 DQA101 等位基因家族。它被提议作为一种抗体验证的 eplet，但还没有得到足够的验证，不足以获得这个标签。特别是，当针对存在于 DQB105 和 DQB106 等位基因家族中的 52PQ eplet 发生反应时，可能会出现混淆，因为 DQ 分子的稳定性要求 DQA101 只能选择性地与这些 DQ-β 家族结合。使用来自两个供应商的两种 Luminex 单抗原 (LSA) 检测试剂盒、带有 DR-α/DQ6 异二聚体的珠子、一个额外的 DQ 珠子的特殊构建 LSA 面板，以及一个仅依赖于已故供体细胞或仅表达一种 DQ 抗原的重组细胞的吸附/洗脱策略，我们使用仅针对 One Lambda LSA 面板的 DQ5 和 DQ6 珠子反应的患者血清，明确地确定了 eplet 52SK 的抗体验证状态在常规患者随访中。我们还表明，针对这种 eplet 的反应在抗-DQ1 免疫中并不是一个罕见事件。这项研究进一步强调了在 HLA 的免疫学研究和器官分配策略中考虑 DQA1 基因座的重要性。
